We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
201
CALL
Novavax
NVAX
$1.23B
$529K 0.03%
51
-150
-75% -$16.1K
RVNC
202
CALL
DELISTED
Revance Therapeutics, Inc.
RVNC
$527K 0.03%
302
-532
-64% -$10.8K
SCON
203
DELISTED
Superconductor Technologies Inc.
SCON
$523K 0.03%
1,823
+256
+16% +$77.8K
VXZ
204
CALL
DELISTED
iPath S&P 500 VIX Mid-Term Futures ETN due 1/30/2019
VXZ
$521K 0.03%
+120
New +$5.87K
ALKS icon
205
Alkermes
ALKS
$8.82B
$513K 0.03%
15,000
-116,671
-89% -$4.61M
CAPR icon
206
Capricor Therapeutics
CAPR
$1.14B
$513K 0.03%
20,208
+1,642
+9% +$39.8K
CDTX
207
DELISTED
Cidara Therapeutics
CDTX
$512K 0.03%
+2,014
New +$464K
FOLD
208
DELISTED
Amicus Therapeutics
FOLD
$501K 0.03%
59,324
+33,663
+131% +$238K
ARCT icon
209
CALL
Arcturus Therapeutics
ARCT
$157M
$497K 0.02%
187
+116
+163% +$3.93K
ADXS
210
PUT
DELISTED
Advaxis Inc
ADXS
$485K 0.02%
+36
New +$3.98K
GILD icon
211
PUT
Gilead Sciences
GILD
$161B
$459K 0.02%
50
-864
-95% -$77.9K
INSM icon
212
Insmed
INSM
$23.2B
$454K 0.02%
+35,867
New +$472K
NVAX icon
213
PUT
Novavax
NVAX
$1.23B
$454K 0.02%
44
-10
-19% -$1.07K
SENS icon
214
Senseonics Holdings Inc
SENS
$254M
$440K 0.02%
+7,695
New +$433K
FLXN
215
DELISTED
Flexion Therapeutics, Inc.
FLXN
$426K 0.02%
+46,355
New +$562K
LUMO
216
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$420K 0.02%
26
-26
-50% -$5.27K
FOCL
217
PUT
EDAP TMS S.A.
FOCL
$226M
$409K 0.02%
1,018
+172
+20% +$666
EGRX
218
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$405K 0.02%
+10,000
New +$634K
EGRX
219
PUT
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$405K 0.02%
+100
New +$6.34K
SPNC
220
CALL
DELISTED
Spectranetics Corp
SPNC
$405K 0.02%
279
+69
+33% +$955
PLUR icon
221
Pluri
PLUR
$19.2M
$404K 0.02%
3,138
-19,520
-86% -$1.83M
NSPR icon
222
InspireMD
NSPR
$32M
$399K 0.02%
+1
New +$383K
RGLS
223
PUT
DELISTED
Regulus Therapeutics
RGLS
$398K 0.02%
5
+1
+25% +$796
CRDF icon
224
Cardiff Oncology
CRDF
$64.3M
$395K 0.02%
1,181
-1,043
-47% -$355K
BHC icon
225
CALL
Bausch Health
BHC
$1.65B
$392K 0.02%
+149
New +$11K
7 8
9
10 11

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.